Ser720
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser720  -  ERK5 (human)

Site Information
VTQQLsKsQVEDPLP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3195185

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 5 )
Disease tissue studied:
melanoma skin cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
nocodazole ( 5 ) , sorbitol ( 5 )

Downstream Regulation
Effects of modification on ERK5:
enzymatic activity, inhibited ( 5 ) , intracellular localization ( 5 )
Effects of modification on biological processes:
transcription, altered ( 5 )

References 

1

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Gilley R, et al. (2012) CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIM(EL). Cell Signal 24, 170-80
21924351   Curated Info

4

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

5

IƱesta-Vaquera FA, et al. (2010) Alternative ERK5 regulation by phosphorylation during the cell cycle. Cell Signal 22, 1829-37
20667468   Curated Info

6

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info